1. Home
  2. TXO vs EMBC Comparison

TXO vs EMBC Comparison

Compare TXO & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TXO Partners L.P.

TXO

TXO Partners L.P.

HOLD

Current Price

$11.82

Market Cap

701.2M

Sector

Energy

ML Signal

HOLD

Logo Embecta Corp.

EMBC

Embecta Corp.

HOLD

Current Price

$11.81

Market Cap

719.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXO
EMBC
Founded
2012
1924
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
701.2M
719.7M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
TXO
EMBC
Price
$11.82
$11.81
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$20.50
$18.50
AVG Volume (30 Days)
309.2K
733.6K
Earning Date
11-04-2025
11-25-2025
Dividend Yield
20.42%
4.99%
EPS Growth
N/A
20.90
EPS
0.36
1.62
Revenue
$364,412,000.00
$1,080,400,000.00
Revenue This Year
$32.78
$2.18
Revenue Next Year
$10.18
$0.09
P/E Ratio
$32.80
$7.43
Revenue Growth
27.66
N/A
52 Week Low
$11.66
$9.20
52 Week High
$20.70
$21.23

Technical Indicators

Market Signals
Indicator
TXO
EMBC
Relative Strength Index (RSI) 29.36 38.69
Support Level $11.90 $11.02
Resistance Level $12.65 $12.56
Average True Range (ATR) 0.32 0.67
MACD -0.05 -0.10
Stochastic Oscillator 17.93 20.72

Price Performance

Historical Comparison
TXO
EMBC

About TXO TXO Partners L.P.

TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.

About EMBC Embecta Corp.

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Share on Social Networks: